Skip to Content

Generic Nuvigil Availability

Nuvigil is a brand name of armodafinil, approved by the FDA in the following formulation(s):

NUVIGIL (armodafinil - tablet;oral)

  • Manufacturer: CEPHALON
    Approval date: June 15, 2007
    Strength(s): 50MG [RLD] [AB], 150MG [RLD] [AB], 250MG [RLD] [AB]
  • Manufacturer: CEPHALON
    Approval date: March 26, 2009
    Strength(s): 100MG [RLD], 200MG [RLD] [AB]

Has a generic version of Nuvigil been approved?

A generic version of Nuvigil has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Nuvigil and have been approved by the FDA:

armodafinil tablet;oral

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: March 6, 2018
    Strength(s): 50MG [AB], 150MG [AB], 250MG [AB]
  • Manufacturer: LUPIN LTD
    Approval date: November 28, 2016
    Strength(s): 50MG [AB], 150MG [AB], 200MG [AB], 250MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: June 1, 2012
    Strength(s): 50MG [AB], 150MG [AB], 250MG [AB]
  • Manufacturer: NATCO PHARMA LTD
    Approval date: November 28, 2016
    Strength(s): 50MG [AB], 150MG [AB], 250MG [AB]
  • Manufacturer: NATCO PHARMA LTD
    Approval date: September 28, 2017
    Strength(s): 200MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuvigil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
    Patent 7,132,570
    Issued: November 7, 2006
    Inventor(s): Neckebrock; Olivier & Leproust; Pierre
    Assignee(s): Cephalon France

    The invention relates to a process for the preparation of crystalline forms of the optical enantiomers of modafinil, comprising stages comprising: i) dissolving one of the optical enantiomers of modafinil in a solvent other than ethanol, ii) crystallising the modafinil enantiomer, iii) recovering the crystalline form of the modafinil enantiomer so obtained. The invention also relates to a process for the preparation of the optical enantiomers of modafinil.

    Patent expiration dates:

    • December 18, 2023
      Drug substance
      Drug product
    • June 18, 2024
      Pediatric exclusivity
  • Pharmaceutical formulations of modafinil
    Patent 7,297,346
    Issued: November 20, 2007
    Inventor(s): Corvari; Vincent & Grandolfi; George & Parikh; Alpa
    Assignee(s): Cephalon Inc.

    The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.

    Patent expiration dates:

    • November 29, 2023
      Drug product
    • May 29, 2024
      Pediatric exclusivity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.